Dr. Reddy's Laboratories Limited (NSE:DRREDDY) disclosed on July 23, 2026 that audio recordings of its earnings call for the quarter ended June 30, 2026, conducted on July 22, 2026, are now available for public access. The company published the weblink to the recording in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Key Highlights
- Dr. Reddy's Laboratories made public the audio recording of its Q1 FY27 earnings call held on July 22, 2026.
- The recording is available via a weblink published on the company's official website under the investor relations section.
- The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- The earnings call covered financial and operational performance for the quarter ended June 30, 2026.
- The announcement was filed with NSE, BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd., the four exchanges where Dr. Reddy's is listed.
About the Company
Dr. Reddy's Laboratories Limited (NSE:DRREDDY, BSE:500124) is a multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. The company develops, manufactures, and markets a portfolio of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and specialty therapeutic drugs. Dr. Reddy's operates manufacturing facilities across multiple geographies and serves customers in the United States, Europe, India, and emerging markets. The company is listed on the National Stock Exchange of India, BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd.
Announcement in Detail
Dr. Reddy's Laboratories disclosed on July 23, 2026 that the audio recording of its earnings call for the quarter ended June 30, 2026 is now available for public access. The earnings call was conducted on July 22, 2026 and featured the company's management discussing financial results, operational performance, and business updates for the first quarter of fiscal year 2027.
The company published the weblink to the audio recording as per its continuous disclosure obligations under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The weblink provided in the filing directs investors to an mp3 file hosted on the company's official website. The announcement was simultaneously filed with all four stock exchanges on which Dr. Reddy's is listed: NSE (Stock Code DRREDDY), BSE Limited (Stock Code 500124), New York Stock Exchange Inc. (Stock Code RDY), and NSE IFSC Ltd. (Stock Code DRREDDY).
Impact on Investors
Investors will note that the public disclosure of the earnings call audio recording provides a transparent and accessible channel to review management's commentary on quarterly financial performance and strategic direction. The audio format allows shareholders and other market participants to review the company's guidance, forward-looking statements, and responses to specific business questions without relying on third-party transcripts or summaries.
The filing demonstrates Dr. Reddy's adherence to SEBI disclosure requirements and provides investors with an auditable record of statements made during the earnings call. Investors reviewing the audio should note that forward-looking statements made during such calls carry inherent risks and uncertainties, and actual results may differ materially from those expressed or implied.
Sector / Market Context
Indian pharmaceutical companies are among the largest manufacturers of generic drugs globally, with significant operations in regulated markets such as the United States and Europe. SEBI has mandated transparency in earnings calls and investor communication through Regulation 30 requirements, which require listed companies to disclose material information promptly. Public availability of earnings call recordings has become standard practice among major pharmaceutical players listed in India, enhancing investor access to management communication and supporting compliance with regulatory frameworks governing listed entities.